Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00439010 · ClinicalTrials.gov registry record · Phase 1
Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects
A Phase 1 study, sponsored by Molecular NeuroImaging.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00439010 is a Phase 1 study that has completed, run by Molecular NeuroImaging. The registered enrollment target is 30 participants.
The verdict
NCT00439010, a Phase 1 study, has completed, sponsored by Molecular NeuroImaging.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The underlying goal of this study is to assess 123-I AV39 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.
Interventions
- DRUG [123I] AV 39
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00439010
The ClinicalTrials.gov registry entry for NCT00439010 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular NeuroImaging, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [123I] AV 39 is the first listed.
NCT00439010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00439010 about?
NCT00439010 is a clinical study titled "Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects". The underlying goal of this study is to assess 123-I AV39 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.
What is the current status of trial NCT00439010?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2007-02. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00439010?
The interventions under investigation include: [123I] AV 39 (DRUG).
Who is sponsoring clinical trial NCT00439010?
This trial is sponsored by Molecular NeuroImaging, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.